Phibro Animal Health (PAHC) Amortization of Deferred Charges (2013 - 2026)
Phibro Animal Health's (PAHC) quarterly Amortization of Deferred Charges came in at $572000.0 in Q1 2026, little changed year-on-year from $572000.0 in Q1 2025, and little changed quarter-over-quarter from $572000.0 in Q4 2025.
Phibro Animal Health (PAHC) Amortization of Deferred Charges (2013 - 2026) Analysis & Trends
Phibro Animal Health's Amortization of Deferred Charges history runs 14 years deep, the most recent figure standing at $572000.0 for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges changed 0.0% year-over-year to $572000.0 in Q1 2026; TTM through Mar 2026 was $2.3 million, a 34.35% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, up 93.75% from the prior year.
- Amortization of Deferred Charges steadied at $572000.0 in Q1 2026 per PAHC's latest filing, from $572000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $572000.0 in Q1 2025 and bottomed at $147000.0 in Q1 2022.
- The 5-year median for Amortization of Deferred Charges is $260000.0 (2023), against an average of $340764.7.
- Across the five-year window, Amortization of Deferred Charges slumped 33.48% in 2022 and surged 120.0% in 2025, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $179000.0 in 2022, then soared by 45.25% to $260000.0 in 2023, then surged by 93.85% to $504000.0 in 2024, then climbed by 13.49% to $572000.0 in 2025, then changed by 0.0% to $572000.0 in 2026.
- Per Business Quant, the three latest PAHC Amortization of Deferred Charges figures stand at $572000.0 (Q1 2026), $572000.0 (Q4 2025), and $572000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.15 Bn | 87.28 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.16 Bn | 1.97 Bn |
| 3 | Zoetis | 32.68 Bn | 30.74 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.59 Bn | 23.53 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.21 Bn | 21.06 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 20.54 Bn | 20.54 Bn | - |
| 7 | Viatris | 20.31 Bn | 18.50 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.83 Bn | 16.51 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.60 Bn | 12.17 Bn | 785.00 Mn |
| 10 | Phibro Animal Health | 1.42 Bn | 1.34 Bn | 125.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 572,000.00 |
| Mar 31, 2026 | 572,000.00 |
| Dec 31, 2025 | 572,000.00 |
| Dec 31, 2025 | 572,000.00 |
| Sep 30, 2025 | 572,000.00 |
| Sep 30, 2025 | 572,000.00 |
| Jun 30, 2025 | 572,000.00 |
| Jun 30, 2025 | 572,000.00 |
| Mar 31, 2025 | 572,000.00 |
| Mar 31, 2025 | 572,000.00 |
| Dec 31, 2024 | 504,000.00 |
| Dec 31, 2024 | 504,000.00 |
| Sep 30, 2024 | 367,000.00 |
| Sep 30, 2024 | 367,000.00 |
| Jun 30, 2024 | 260,000.00 |
| Jun 30, 2024 | 260,000.00 |
| Mar 31, 2024 | 260,000.00 |
| Mar 31, 2024 | 260,000.00 |
| Dec 31, 2023 | 260,000.00 |
| Dec 31, 2023 | 260,000.00 |